IκBα kinase inhibitor demonstrates antitumor activity in RAS-driven tumor models
July 16, 2024
Transcriptome-wide gene expression analyses revealed that oncogenic forms of NRAS, KRAS and HRAS (HRAS V12, KRAS V12 and NRAS Q61K) activated the expression of several genes, including IκBα.
